Reynders McVeigh Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.46M Sell
9,072
-118
-1% -$64K 0.23% 60
2025
Q4
$5.33M Sell
9,190
-201
-2% -$114K 0.25% 59
2025
Q3
$4.55M Sell
9,391
-319
-3% -$148K 0.21% 62
2025
Q2
$3.94M Buy
9,710
+45
+0.5% +$18.8K 0.2% 64
2025
Q1
$4.81M Sell
9,665
-816
-8% -$442K 0.27% 56
2024
Q4
$5.45M Sell
10,481
-73
-0.7% -$40.1K 0.29% 55
2024
Q3
$6.53M Buy
10,554
+111
+1% +$65.7K 0.35% 50
2024
Q2
$5.78M Buy
10,443
+165
+2% +$94.5K 0.33% 51
2024
Q1
$5.97M Sell
10,278
-171
-2% -$96K 0.34% 54
2023
Q4
$5.55M Sell
10,449
-735
-7% -$356K 0.35% 54
2023
Q3
$5.66M Sell
11,184
-115
-1% -$61.3K 0.39% 46
2023
Q2
$5.89M Sell
11,299
-119
-1% -$64.2K 0.39% 46
2023
Q1
$6.58M Sell
11,418
-264
-2% -$149K 0.45% 44
2022
Q4
$6.43M Sell
11,682
-216
-2% -$114K 0.47% 45
2022
Q3
$6.04M Sell
11,898
-232
-2% -$130K 0.47% 46
2022
Q2
$6.59M Sell
12,130
-181
-1% -$99.6K 0.49% 46
2022
Q1
$7.27M Sell
12,311
-263
-2% -$151K 0.44% 45
2021
Q4
$8.39M Sell
12,574
-142
-1% -$88.7K 0.48% 44
2021
Q3
$7.26M Buy
12,716
+189
+2% +$104K 0.44% 45
2021
Q2
$6.32M Sell
12,527
-297
-2% -$140K 0.39% 47
2021
Q1
$5.85M Sell
12,824
-286
-2% -$137K 0.39% 45
2020
Q4
$6.11M Sell
13,110
-14
-0.1% -$6.56K 0.42% 44
2020
Q3
$5.79M Sell
13,124
-423
-3% -$175K 0.45% 45
2020
Q2
$4.91M Buy
13,547
+345
+3% +$116K 0.43% 45
2020
Q1
$3.74M Sell
13,202
-268
-2% -$84.5K 0.43% 44
2019
Q4
$4.38M Sell
13,470
-495
-4% -$150K 0.42% 46
2019
Q3
$4.07M Sell
13,965
-50
-0.4% -$14.3K 0.43% 45
2019
Q2
$4.12M Buy
14,015
+165
+1% +$45.4K 0.44% 44
2019
Q1
$3.79M Sell
13,850
-185
-1% -$46K 0.42% 44
2018
Q4
$3.14M Sell
14,035
-205
-1% -$48.1K 0.42% 49
2018
Q3
$3.48M Sell
14,240
-47
-0.3% -$10.8K 0.41% 50
2018
Q2
$2.96M Buy
14,287
+29
+0.2% +$6.16K 0.38% 53
2018
Q1
$2.94M Sell
14,258
-58
-0.4% -$12.2K 0.37% 50
2017
Q4
$2.72M Sell
14,316
-11
-0.1% -$2.11K 0.36% 53
2017
Q3
$2.71M Sell
14,327
-25
-0.2% -$4.53K 0.35% 55
2017
Q2
$2.5M Sell
14,352
-225
-2% -$37.8K 0.34% 62
2017
Q1
$2.24M Buy
14,577
+925
+7% +$141K 0.31% 66
2016
Q4
$1.93M Buy
13,652
+355
+3% +$52.3K 0.27% 69
2016
Q3
$2.12M Sell
13,297
-545
-4% -$84K 0.31% 61
2016
Q2
$2.04M Buy
13,842
+2,310
+20% +$341K 0.3% 66
2016
Q1
$1.63M Buy
11,532
+509
+5% +$68.2K 0.24% 77
2015
Q4
$1.56M Buy
11,023
+98
+0.9% +$13.1K 0.26% 66
2015
Q3
$1.34M Sell
10,925
-152
-1% -$19.8K 0.23% 73
2015
Q2
$1.44M Buy
11,077
+1,215
+12% +$158K 0.23% 67
2015
Q1
$1.32M Sell
9,862
-949
-9% -$122K 0.23% 73
2014
Q4
$1.35M Buy
10,811
+290
+3% +$35.3K 0.24% 73
2014
Q3
$1.28M Hold
10,521
0.24% 71
2014
Q2
$1.24M Buy
10,521
+125
+1% +$14.7K 0.28% 68
2014
Q1
$1.25M Sell
10,396
-25
-0.2% -$2.97K 0.3% 65
2013
Q4
$1.16M Buy
10,421
+16
+0.2% +$1.59K 0.29% 68
2013
Q3
$959K Hold
10,405
0.27% 72
2013
Q2
$881K Buy
+10,405
New +$866K 0.26% 72

Other funds holding TMO

Reynders McVeigh Capital Management's TMO Position: Q1 2026 in Review

Reynders McVeigh Capital Management reduced its Thermo Fisher Scientific (TMO) stake by 1.3% in Q1 2026, selling an estimated $64K and leaving 9,072 shares worth $4.46M. The position accounts for 0.23% of the portfolio, ranked #60.

Reynders McVeigh Capital Management first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.39M in Q4 2021. 2,590 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Reynders McVeigh Capital Management held 9,072 shares of Thermo Fisher Scientific worth $4.46M as of Q1 2026.
  • Reynders McVeigh Capital Management sold 118 Thermo Fisher Scientific shares in Q1 2026, an estimated $64K.
  • Thermo Fisher Scientific made up 0.23% of Reynders McVeigh Capital Management's portfolio in Q1 2026, its #60 holding.
  • Reynders McVeigh Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • Reynders McVeigh Capital Management's Thermo Fisher Scientific position peaked at $8.39M in Q4 2021.
  • 2,590 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.